Glioblastoma in Natalizumab-treated Multiple Sclerosis Patients

Overview

Journal Ann Clin Transl Neurol

Specialty Neurology

Date 2017 Jul 12

PMID 28695151

Citations 5

Authors

Fabian Sierra Morales

Robert B Wright

Jorge E Novo

Leonidas D Arvanitis

Dusan Stefoski

Igor J Koralnik

Affiliations

Soon will be listed here.

Abstract

We present two natalizumab-treated multiple sclerosis patients who developed glioblastoma multiforme (GBM) with variable outcomes. One patient had an isocitrate dehydrogenase (IDH)-wildtype GBM with aggressive behavior, who declined treatment and died 13 weeks after symptoms onset. The other patient underwent resection of an IDH-mutant secondary GBM that arose from a previously diagnosed grade II astrocytoma. He is still alive 5 years after the diagnosis of GBM. JC virus was not detected in either case. Whether natalizumab played a role in the development of GBM in those patients deserves further investigation.

Citing Articles

Concurrent gliomas in patients with multiple sclerosis.

Sahm K, Kessler T, Eisele P, Ratliff M, Sperk E, Konig L Commun Med (Lond). 2023; 3(1):186.

PMID: 38110626 PMC: 10728097. DOI: 10.1038/s43856-023-00381-y.

Glioblastoma in Patients With Multiple Sclerosis.

Berkman J, Nakhate V, Gonzalez Castro L Neurohospitalist. 2022; 12(4):607-616.

PMID: 36147751 PMC: 9485692. DOI: 10.1177/19418744221106003.

First Report of Tumor Treating Fields (TTFields) Therapy for Glioblastoma in Comorbidity with Multiple Sclerosis.

Kassubek R, Mathieu R Brain Sci. 2022; 12(4).

PMID: 35448029 PMC: 9032427. DOI: 10.3390/brainsci12040499.

Upper Gastrointestinal Tract Lymphoma With Natalizumab: Evidence of Impaired Immune Surveillance?.

Gomes L, Watson E, Smith M, Morris E, Boggild M Neurol Clin Pract. 2021; 11(4):e546-e548.

PMID: 34484954 PMC: 8382421. DOI: 10.1212/CPJ.0000000000000985.

Diagnostic Dilemma: An Atypical Case of Astrocytoma in a Patient with Relapsing-Remitting Multiple Sclerosis.

Kahovec C, Saini A, Levin M Neurol Int. 2021; 13(2):240-251.

PMID: 34204935 PMC: 8293366. DOI: 10.3390/neurolint13020025.

References

Mullen J, Vartanian T, Atkins M . Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med. 2008; 358(6):647-8. DOI: 10.1056/NEJMc0706103. View

Turkalp Z, Karamchandani J, Das S . IDH mutation in glioma: new insights and promises for the future. JAMA Neurol. 2014; 71(10):1319-25. DOI: 10.1001/jamaneurol.2014.1205. View

Compston A, Coles A . Multiple sclerosis. Lancet. 2008; 372(9648):1502-17. DOI: 10.1016/S0140-6736(08)61620-7. View

Rudick R, Stuart W, Calabresi P, Confavreux C, Galetta S, Radue E . Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006; 354(9):911-23. DOI: 10.1056/NEJMoa044396. View

OConnor P, Goodman A, Kappos L, Lublin F, Polman C, Rudick R . Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology. 2014; 83(1):78-86. PMC: 4114173. DOI: 10.1212/WNL.0000000000000541. View

Bergamaschi R, Montomoli C . Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence?. Mult Scler. 2009; 15(12):1532-3. DOI: 10.1177/1352458509347154. View

Hofer S, Linnebank M, Weller M, Bahmanyar S, Montgomery S, Hillert J . Cancer risk among patients with multiple sclerosis and their parents. Neurology. 2010; 74(7):614-5. DOI: 10.1212/WNL.0b013e3181c777b7. View

Li Y, Min W, Li M, Han G, Dai D, Zhang L . Identification of hub genes and regulatory factors of glioblastoma multiforme subgroups by RNA-seq data analysis. Int J Mol Med. 2016; 38(4):1170-8. PMC: 5029949. DOI: 10.3892/ijmm.2016.2717. View

Pharaon M, Tichet M, Lebrun-Frenay C, Tartare-Deckert S, Passeron T . Risk for nevus transformation and melanoma proliferation and invasion during natalizumab treatment: four years of dermoscopic follow-up with immunohistological studies and proliferation and invasion assays. JAMA Dermatol. 2014; 150(8):901-3. DOI: 10.1001/jamadermatol.2013.9411. View

10.

Hemminki K, Liu X, Forsti A, Ji J, Sundquist J, Sundquist K . Subsequent brain tumors in patients with autoimmune disease. Neuro Oncol. 2013; 15(9):1142-50. PMC: 3748918. DOI: 10.1093/neuonc/not070. View

11.

Polman C, OConnor P, Havrdova E, Hutchinson M, Kappos L, Miller D . A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006; 354(9):899-910. DOI: 10.1056/NEJMoa044397. View

12.

Laroni A, Bedognetti M, Uccelli A, Capello E, Mancardi G . Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. Neurol Sci. 2010; 32(1):181-2. DOI: 10.1007/s10072-010-0427-x. View

13.

Scalici J, Harrer C, Allen A, Jazaeri A, Atkins K, McLachlan K . Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin. Gynecol Oncol. 2014; 132(2):455-61. PMC: 3939448. DOI: 10.1016/j.ygyno.2013.12.031. View

14.

Korshunov A, Sycheva R, Golanov A . The prognostic relevance of molecular alterations in glioblastomas for patients age < 50 years. Cancer. 2005; 104(4):825-32. DOI: 10.1002/cncr.21221. View

15.

Planas R, Martin R, Sospedra M . Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life. Patient Relat Outcome Meas. 2014; 5:25-33. PMC: 3983075. DOI: 10.2147/PROM.S41768. View

16.

Schweikert A, Kremer M, Ringel F, Liebig T, Duyster J, Stuve O . Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol. 2009; 66(3):403-6. DOI: 10.1002/ana.21782. View

17.

Carbonell W, Delay M, Jahangiri A, Park C, Aghi M . β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res. 2013; 73(10):3145-54. PMC: 4040366. DOI: 10.1158/0008-5472.CAN-13-0011. View

18.

Law J, Kim D, Sturgis A, Naina H . Non-Hodgkin Lymphoma of the Stomach in a Patient Treated with Natalizumab. Clin Med Insights Oncol. 2015; 9:61-3. PMC: 4489670. DOI: 10.4137/CMO.S27142. View

19.

Stuve O, Marra C, Jerome K, Cook L, Cravens P, Cepok S . Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006; 59(5):743-7. DOI: 10.1002/ana.20858. View

20.

Fadul C, Fisher J, Hampton T, Lallana E, Li Z, Gui J . Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother. 2011; 34(4):382-9. PMC: 3766324. DOI: 10.1097/CJI.0b013e318215e300. View